Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1
- PMID: 25676581
- DOI: 10.1517/14656566.2015.1013938
Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1
Abstract
Introduction: The recent October 2014 approval of the fixed dose combination (FDC) of the NS5B polymerase inhibitor sofosbuvir (SOF) and the NS5A inhibitor ledipasvir (LDV) for the treatment of treatment-naive and -experienced HCV genotype 1a/1b (HCV-1) has marked a new era of IFN and ribavirin free treatment for chronic hepatitis C. SOF/LDV combination is approved for 12 weeks in treatment-naive patients with and without cirrhosis. For treatment-experienced patients, it is approved for 12 weeks in patients without cirrhosis but for 24 weeks in patients with cirrhosis. A shorter 8-week course of treatment can be considered for treatment-naive patients who have pretreatment HCV RNA of < 6 million IU/ml and do not have cirrhosis.
Areas covered: The purpose of this synopsis is to review the pharmacotherapy and results of pivotal clinical trials for SOF/LDV as the current standard-of-care for HCV-1 patients. We also briefly discuss emerging data with SOF/LDV for certain special populations. Preliminary data is also emerging for HCV genotypes non-1, but their discussion is beyond the scope of this synopsis. The review was done based on data from Phase I, II and III published studies as well as data presented at major national and international meetings.
Expert opinion: The FDC of LDV (90 mg) and SOF (400 mg) has a sustained virologic response of approximately 96% when given as a once-a-day pill for 3 months to both treatment-naive and -experienced HCV-1 patients with the exception of prior null responders with cirrhosis. The latter group of patients also achieves high sustained virologic response of 95% but with therapy for 24 weeks. In addition, emerging data suggest that this FDC regimen may be effective in the treatment of HCV-1 co-infected patients with HIV, HCV-1 and -4, patients with cirrhosis and hepatic decompensation and those with post-liver transplant HCV recurrence.
Keywords: HCV; chronic hepatitis C; direct acting antivirals; fixed-dose combination; ledipasvir; sofosbuvir.
Similar articles
-
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.Gastroenterology. 2014 Mar;146(3):736-743.e1. doi: 10.1053/j.gastro.2013.11.007. Epub 2013 Nov 18. Gastroenterology. 2014. PMID: 24262278 Clinical Trial.
-
Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.J Viral Hepat. 2016 Oct;23(10):780-8. doi: 10.1111/jvh.12549. Epub 2016 May 15. J Viral Hepat. 2016. PMID: 27196675
-
Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.Eur J Gastroenterol Hepatol. 2018 Mar;30(3):291-295. doi: 10.1097/MEG.0000000000001027. Eur J Gastroenterol Hepatol. 2018. PMID: 29120906
-
Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.Ann Pharmacother. 2015 Mar;49(3):343-50. doi: 10.1177/1060028014563952. Epub 2014 Dec 16. Ann Pharmacother. 2015. PMID: 25515863 Review.
-
Ledipasvir + sofosbuvir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties.Prescrire Int. 2015 Dec;24(166):285-9. Prescrire Int. 2015. PMID: 26788571 Review.
Cited by
-
Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.Hepatol Int. 2018 May;12(3):214-222. doi: 10.1007/s12072-018-9873-y. Epub 2018 May 29. Hepatol Int. 2018. PMID: 29845496 Free PMC article. Review.
-
Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy.Hepatol Int. 2017 Mar;11(2):161-170. doi: 10.1007/s12072-016-9776-8. Epub 2016 Dec 7. Hepatol Int. 2017. PMID: 27928718 Review.
-
Recent Updates on Viral Oncogenesis: Available Preventive and Therapeutic Entities.Mol Pharm. 2023 Aug 7;20(8):3698-3740. doi: 10.1021/acs.molpharmaceut.2c01080. Epub 2023 Jul 24. Mol Pharm. 2023. PMID: 37486263 Free PMC article. Review.
-
Diastereoselective Synthesis of Spirocyclopropanes under Mild Conditions via Formal [2 + 1] Cycloadditions Using 2,3-Dioxo-4-benzylidene-pyrrolidines.Molecules. 2017 Feb 22;22(2):328. doi: 10.3390/molecules22020328. Molecules. 2017. PMID: 28241452 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources